{"id":4701,"date":"2019-04-09T16:07:16","date_gmt":"2019-04-09T10:37:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4701"},"modified":"2021-07-24T12:57:17","modified_gmt":"2021-07-24T07:27:17","slug":"notizia-nash","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-nash","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f8a0d82cdfd\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f8a0d82cdfd\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash\/#Anylam_Regeneron_to_broaden_the_scope_of_R_D_in_Pharma\" >Anylam, Regeneron to broaden the scope of R&amp;D in Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash\/#Drugs_to_Train_Immune_cells_to_Target_Cancer\" >Drugs to Train Immune cells to Target Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash\/#Audentes_is_a_new_Hope_for_DMD_patients\" >Audentes is a new Hope for DMD patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash\/#FDA_grants_approval_to_Dovato\" >FDA grants approval to Dovato<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"has-text-align-left wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anylam_Regeneron_to_broaden_the_scope_of_R_D_in_Pharma\"><\/span><strong>Anylam, Regeneron to broaden the scope of R&amp;D in Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Alnylam <\/strong>in collaboration with <strong>Regeneron <\/strong>is expanding its research on <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\">NASH<\/a><\/strong>. Regeneron with the capability of generating various targets via<strong> antibody approach<\/strong> is going to get infused with <strong>USD 800 million <\/strong>upfront. The joint deal will help in expanding R&amp;D and reaching the extracellular targets. Although priority will be on testing a combination of <g class=\"gr_ gr_27 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"27\" data-gr-id=\"27\">pozelimab<\/g>, Regeneron&#8217;s C5 antibody in Phase 1 trial and <g class=\"gr_ gr_30 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"30\" data-gr-id=\"30\">cemdisiran<\/g>, Alnylam&#8217;s RNAi anti-C5 therapy, now in Phase 2.<\/p>\n\n\n\n<h4 class=\"has-text-align-left wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drugs_to_Train_Immune_cells_to_Target_Cancer\"><\/span><strong>Drugs to Train Immune cells to Target Cancer <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-text-align-left\">Researchers at <strong>Mount Sinai School of Medicine<\/strong> in New York, have positive outcomes that FDA approved approaches for <strong>CAR-T<\/strong>. It involves directly removing the T-cells from patients that can be used to target <strong>cancer<\/strong>. This approach to train immune cells to hunt down the cancerous cells via \u201c<strong>in-situ vaccination<\/strong>\u201d will be open for not only treating <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-lymphomas-market\">Lymphoma<\/a><\/strong>, <strong>Neck cancer<\/strong> but also <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market\">Breast cancer<\/a><\/strong>. The Vaccination consists of two drugs which will be administered at the tumour site. <\/p>\n\n\n\n<h4 class=\"has-text-align-left wp-block-heading\"><span class=\"ez-toc-section\" id=\"Audentes_is_a_new_Hope_for_DMD_patients\"><\/span><strong>Audentes is a new Hope for DMD patients<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Audentes Therapeutics-<\/strong>a California based Biotechnology company, has started to accelerate the production of a <strong>muscle-repair protein <\/strong>whose deficiency is the primary cause of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market-insight-epidemiology-and-market-forecast\">Duchenne muscular dystrophy (DMD)<\/a>.<\/strong> Duchenne is one of the most competitive areas, and Audentes doesn\u2019t want <strong>Sarepta&#8217;s Exondys 51<\/strong> to monopolise the market. The collaboration with the <strong>Nationwide&#8217;s Children Hospital in Columbus,<\/strong> Ohio, focuses on the approach to stimulate a version of the protein- <strong>dystrophin<\/strong>, missing in DMD patients due to mutations in genes.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_grants_approval_to_Dovato\"><\/span> <strong>FDA grants approval to <g class=\"gr_ gr_6 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"6\" data-gr-id=\"6\">Dovato<\/g><\/strong> <br><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The <strong>U.S. Food and Drug Administration (<\/strong>FDA) recently has given thumbs-up to a combined therapy of <strong class=\"\">Dovato, <\/strong>submitted by ViiV healthcare, which comprises two drugs <strong class=\"\"><g class=\"gr_ gr_5 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"5\" data-gr-id=\"5\">dolutegravir<\/g><\/strong><strong> <\/strong>and <strong>lamivudine<\/strong>. The new regimen approved will be effective to treat patients infected with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hiv-associated-lipodystrophy-market\">HIV<\/a> <\/strong>who have never received the treatment before to take the drugs in a sing tablet. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anylam, Regeneron to broaden the scope of R&amp;D in Pharma Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody approach is going to get infused with USD 800 million upfront. The joint deal will help in expanding R&amp;D and reaching the extracellular targets. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4710,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1482,127,3106,704,297,667,1469,1510,2581],"industry":[17225],"therapeutic_areas":[17245,17228,17234],"class_list":["post-4701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alnylam-pharmaceuticals","tag-breast-cancer","tag-dovato","tag-fda","tag-hiv","tag-lymphoma","tag-nash","tag-regeneron-pharmaceuticals","tag-sarepta-therapeutics","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 09\/04\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 09\/04\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-09T10:37:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09023725\/My-Post.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 09\/04\/2019 - DelveInsight Business Research","description":"Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-nash","og_locale":"en_US","og_type":"article","og_title":"Notizia 09\/04\/2019 - DelveInsight Business Research","og_description":"Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-nash","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-09T10:37:16+00:00","article_modified_time":"2021-07-24T07:27:17+00:00","og_image":[{"width":800,"height":400,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09023725\/My-Post.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash","url":"https:\/\/www.delveinsight.com\/blog\/notizia-nash","name":"Notizia 09\/04\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09023725\/My-Post.jpg","datePublished":"2019-04-09T10:37:16+00:00","dateModified":"2021-07-24T07:27:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-nash"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09023725\/My-Post.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09023725\/My-Post.jpg","width":800,"height":400},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09023725\/My-Post-300x150.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dovato<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sarepta Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Dovato<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">lymphoma<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Sarepta Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 9, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 9, 2019 4:07 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4701"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4701\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4710"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4701"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4701"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}